CLPTM1L and ovarian neoplasm: We found that treatment with 102-5 anti-CLPTM1L resulted in a single major band consistent with 62 kDa CLPTM1L, which concurred with results using commercial anti-CLPTM1L and demonstrated upregulation of CLPTM1L accumulation in cisplatin-resistant ovarian tumor cells compared to parental cisplatin-sensitive cells (Fig. 2a and Supplementary Figs. 1b and 2).